Bolivia OBSERVADO Response: Managing the 60 Calendar Day Correction Window
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
After AGEMED issues an OBSERVADO determination, it releases a notification listing correctable technical observations, and the applicant has 60 calendar days to respond (Chapter 3 of the manual). Three points decide whether the response succeeds: first, organise the response item by item against the numbered observations; second, advance the Spanish translation in parallel with the original-language work, because the response documents are subject to the same Spanish requirement; third, file the response in the first half of the window rather than at the deadline. GRZAN’s assessment is that the observation round itself attracts no additional official fee, but the time it consumes routinely exceeds expectations, because the translation and legalisation chain has to be walked through completely a second time.
The notification that opens the window is operational in character: it enumerates the correctable technical observations with enough specificity that each can be answered individually, and it is on that enumeration that the response architecture should be built. GRZAN treats the notice as the de facto specification for the response package — every numbered observation becomes a tracked item with an owner, a document, and a translation status, and no response is filed until every item reaches a closed state. Managed this way, the 60 calendar day window is sufficient even for files with substantial documentation work, whereas unmanaged responses routinely consume the full window on coordination alone.
2. Legal basis
| Regulation | Reference | Publication date | Provision |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version published on the AGEMED website | Chapter 3 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version published on the AGEMED website | Section 2.7 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version published on the AGEMED website | Section 2.5 |
| Resolución Ministerial (fees and procedures) | Resolución Ministerial N° 0265 | May 25, 2018 | Full text |
The provisions interact in a specific way during an observation round. Chapter 3 opens the 60 calendar day window and defines its consequences; Section 2.7 governs the documentation that a response typically must address; Section 2.5 defines the labelling requirements that recur as observation items. Resolución Ministerial N° 0265 remains the fee reference in case the file later slides from observation into rejection, where a new payment becomes necessary.
The Spanish requirement applies to the response with the same force as to the original dossier, and this is where most window time is lost. New or amended documents — test reports, declarations, labelling artwork — must be translated by qualified translators, and any certification attached to them follows its own issue calendar. Starting translation on the day the notice arrives, in parallel with the technical work, is the single highest-leverage decision of the round; running translation after the technical work is the single most common cause of last-day filing.
3. Expert insights
Insight 1: 60 calendar days do not equal 60 business days. The manual uses calendar days (días calendario), which leaves roughly a little over 40 usable business days. A company that reads the window as 60 business days will exceed it directly. This distinction recurs across Latin American registrations and is a basic but high-frequency error with severe consequences: a missed window closes the file.
Insight 2: the observation notice is a free documentation-gap patch. It lists, item by item, what AGEMED considers missing or non-conforming. GRZAN converts every observation record into an internal Bolivia documentation baseline for the company, so that the first-round pass rate of subsequent products improves step by step — this is the method for turning the observation rate from a cost into an asset.
Insight 3: last-day filing consumes the margin for error. Where the response is filed at the end of the window and further gaps are found, the file can slide toward rejection, at which point a new payment is required. Filing early preserves the time buffer needed for a second correction within the same window.
The 40-business-day reality of a 60-calendar-day window also interacts with reviewer availability. Responses filed late in the window join whatever queue conditions exist at that moment, and a file that slides from observation toward rejection forfeits the entire investment of the round. Early filing is therefore not only a scheduling preference but a risk control: it preserves the possibility of a supplementary correction inside the same window, which is the cheapest recovery mechanism the procedure offers.
4. Practical recommendations
- Start translation on the day the notice is received, running it in parallel with the technical work, never in series.
- Put a three-column comparison table of observation, response, and attachment on the first page of the response, so the reviewer can verify each item quickly.
- Set an internal deadline of 30 calendar days as a buffer (practical estimate), avoiding submission in the final stretch of the window.
Response quality is measured by reviewer effort, not applicant effort. A reviewer who can match every numbered observation to an answer and an attachment in seconds is a reviewer who does not need to raise follow-up questions. Companies that format responses for verification speed consistently close observation rounds faster than companies that respond with long narrative letters.
Finally, institutionalise the learning. Every closed observation round should end with a short internal review — which items appeared, which documents were implicated, which translations caused friction — and the conclusions should flow back into the documentation baseline for the next product. Companies that run this loop convert each observation round into a permanent reduction of future observation risk, which is the only durable way to improve first-round outcomes in a market where the base rate is high.
5. Verification checklist
- □ Confirm the notice uses calendar days, not business days
- □ Confirm the response maps item by item to the AGEMED observation numbers
- □ Confirm all newly added documents have completed Spanish translation
- □ Confirm the internal deadline is at least 30 calendar days before the official window closes
- □ Confirm the present observation has been consolidated into the company documentation baseline
GRZAN registration support. GRZAN provides medical device registration support in Bolivia for manufacturers, importers, and authorized representatives, including OBSERVADO response management, certified Spanish translation coordination, and AGEMED follow-up. For project inquiries, contact info@grzanglobal.com.
Regulatory information verified as of October 29, 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us